CN114246925A - Traditional Chinese medicine essential oil and application thereof - Google Patents
Traditional Chinese medicine essential oil and application thereof Download PDFInfo
- Publication number
- CN114246925A CN114246925A CN202011002501.5A CN202011002501A CN114246925A CN 114246925 A CN114246925 A CN 114246925A CN 202011002501 A CN202011002501 A CN 202011002501A CN 114246925 A CN114246925 A CN 114246925A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- coronavirus
- chinese medicine
- extract
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 129
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 59
- 241000711573 Coronaviridae Species 0.000 claims abstract description 45
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 26
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 18
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 18
- 241000735527 Eupatorium Species 0.000 claims abstract description 16
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 14
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 13
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 13
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 13
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 12
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 11
- 244000166675 Cymbopogon nardus Species 0.000 claims abstract description 10
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 9
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 241000218378 Magnolia Species 0.000 claims abstract description 8
- 235000004347 Perilla Nutrition 0.000 claims abstract description 8
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 8
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 6
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract 2
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229940096437 Protein S Drugs 0.000 claims description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 15
- 101710198474 Spike protein Proteins 0.000 claims description 15
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 14
- 244000063299 Bacillus subtilis Species 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 241000315672 SARS coronavirus Species 0.000 claims description 13
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 241000202726 Bupleurum Species 0.000 claims description 11
- 241000607618 Vibrio harveyi Species 0.000 claims description 10
- 239000002199 base oil Substances 0.000 claims description 9
- 241000607471 Edwardsiella tarda Species 0.000 claims description 8
- 235000020230 cinnamon extract Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001256 steam distillation Methods 0.000 claims description 8
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 7
- 241000607594 Vibrio alginolyticus Species 0.000 claims description 7
- 235000008216 herbs Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000008169 grapeseed oil Substances 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- 238000000222 aromatherapy Methods 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 239000000645 desinfectant Substances 0.000 claims description 4
- 241000607598 Vibrio Species 0.000 claims description 3
- 241000607534 Aeromonas Species 0.000 claims description 2
- 244000144725 Amygdalus communis Species 0.000 claims description 2
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 2
- 241000220317 Rosa Species 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 241000288673 Chiroptera Species 0.000 claims 2
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 11
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 241000212948 Cnidium Species 0.000 abstract description 2
- 241000555682 Forsythia x intermedia Species 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 35
- 230000000840 anti-viral effect Effects 0.000 description 22
- 230000000844 anti-bacterial effect Effects 0.000 description 19
- 241000628997 Flos Species 0.000 description 18
- 241000700605 Viruses Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 241000723347 Cinnamomum Species 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 9
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 9
- 241001570521 Lonicera periclymenum Species 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 241000245665 Taraxacum Species 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- -1 aromatherapy Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 230000002633 protecting effect Effects 0.000 description 5
- 230000035943 smell Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 235000019476 oil-water mixture Nutrition 0.000 description 4
- LVHLZMUFIYAEQB-UHFFFAOYSA-N perilla ketone Chemical compound CC(C)CCC(=O)C=1C=COC=1 LVHLZMUFIYAEQB-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 240000004784 Cymbopogon citratus Species 0.000 description 3
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229930192014 saikosaponin Natural products 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- RXBQNMWIQKOSCS-UHFFFAOYSA-N (7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methanol Chemical compound C1C2C(C)(C)C1CC=C2CO RXBQNMWIQKOSCS-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- OQIOHYHRGZNZCW-UHFFFAOYSA-N 2-methyl-5-propan-2-ylbenzene-1,4-diol Chemical compound CC(C)C1=CC(O)=C(C)C=C1O OQIOHYHRGZNZCW-UHFFFAOYSA-N 0.000 description 2
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- 241000112286 Bat SARS-like coronavirus Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 2
- 241001354243 Corona Species 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- KRCZYMFUWVJCLI-UHFFFAOYSA-N Dihydrocarveol Chemical compound CC1CCC(C(C)=C)CC1O KRCZYMFUWVJCLI-UHFFFAOYSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- PGCKDCPTJAQQSQ-UHFFFAOYSA-N Isolicoflavonol Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 PGCKDCPTJAQQSQ-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 240000000513 Santalum album Species 0.000 description 2
- 235000008632 Santalum album Nutrition 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- LSQXNMXDFRRDSJ-UHFFFAOYSA-N Thymol methyl ether Chemical compound COC1=CC(C)=CC=C1C(C)C LSQXNMXDFRRDSJ-UHFFFAOYSA-N 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- IGWDEVSBEKYORK-UHFFFAOYSA-N isoimperatorin Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)C IGWDEVSBEKYORK-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- RUMOYJJNUMEFDD-UHFFFAOYSA-N perillyl aldehyde Chemical compound CC(=C)C1CCC(C=O)=CC1 RUMOYJJNUMEFDD-UHFFFAOYSA-N 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- DGZBGCMPRYFWFF-ZYOSVBKOSA-N (1s,5s)-6-methyl-4-methylidene-6-(4-methylpent-3-enyl)bicyclo[3.1.1]heptane Chemical compound C1[C@@H]2C(CCC=C(C)C)(C)[C@H]1CCC2=C DGZBGCMPRYFWFF-ZYOSVBKOSA-N 0.000 description 1
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- SFEUTIOWNUGQMZ-UHFFFAOYSA-N (4,4,6a,6b,8a,12,14b-heptamethyl-11-methylidene-1,2,3,4a,5,6,6a,7,8,9,10,12,12a,13,14,14a-hexadecahydropicen-3-yl) acetate Chemical compound CC12CCC(OC(C)=O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(=C)CCC3(C)CCC21C SFEUTIOWNUGQMZ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- XMKLTEGSALONPH-UHFFFAOYSA-N 1,2,4,5-tetrazinane-3,6-dione Chemical compound O=C1NNC(=O)NN1 XMKLTEGSALONPH-UHFFFAOYSA-N 0.000 description 1
- BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical compound CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- ZPSAEGUNYMEKBP-UHFFFAOYSA-N 5-Isopentenyloxy-psoralen Natural products CC(C)C=COc1c2C=CC(=O)Oc2cc3occc13 ZPSAEGUNYMEKBP-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- BEYIWVKWKJROGZ-UHFFFAOYSA-N Alloimperatorin Natural products O1C(=O)C=CC2=C1C(O)=C1OC=CC1=C2OCC=C(C)C BEYIWVKWKJROGZ-UHFFFAOYSA-N 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000202722 Bupleurum falcatum Species 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 1
- HUZJLWLCLJEXEL-NFAWXSAZSA-N Curcumenone Chemical compound C1C(=C(C)C)C(=O)C[C@@]2(C)[C@H](CCC(=O)C)[C@H]21 HUZJLWLCLJEXEL-NFAWXSAZSA-N 0.000 description 1
- HUZJLWLCLJEXEL-UHFFFAOYSA-N Curcumenone Natural products C1C(=C(C)C)C(=O)CC2(C)C(CCC(=O)C)C21 HUZJLWLCLJEXEL-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241001083514 Gayophytum Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 1
- NGGYSPUAKQMTNP-UHFFFAOYSA-N Glabrene Chemical compound C1=C(O)C=C2OCC(C3=C4OC(C=CC4=C(O)C=C3)(C)C)=CC2=C1 NGGYSPUAKQMTNP-UHFFFAOYSA-N 0.000 description 1
- KKLOCFOZPFGVBB-UHFFFAOYSA-N Glabrene Natural products C1=C(O)C=C2OCC(C3=CC=C4OC(C=CC4=C3O)(C)C)=CC2=C1 KKLOCFOZPFGVBB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N Glycyrrhetinic acid Natural products C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000497005 Ixophorus unisetus Species 0.000 description 1
- PUPKKEQDLNREIM-UHFFFAOYSA-N Kaempferitin Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(OC3C(C(O)C(O)C(C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-UHFFFAOYSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000218394 Magnolia liliiflora Species 0.000 description 1
- KGGUASRIGLRPAX-UHFFFAOYSA-N Meranzin hydrate Natural products C1=CC(=O)OC2=C(CC(O)C(C)(C)O)C(OC)=CC=C21 KGGUASRIGLRPAX-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- RXBQNMWIQKOSCS-RKDXNWHRSA-N Myrtenol Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2CO RXBQNMWIQKOSCS-RKDXNWHRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241001607869 Plantagineae Species 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000531819 Streptomyces venezuelae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 230000002353 algacidal effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229930000766 bergamotene Natural products 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 229930003633 citronellal Natural products 0.000 description 1
- 235000000983 citronellal Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 1
- 239000008540 curcumenone Substances 0.000 description 1
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229930007024 dihydrocarveol Natural products 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- ZMGSKTZDVIZXJS-UHFFFAOYSA-N kaempferitrin Natural products CC1OC(OC2C(Oc3cc(OC4OC(C)C(O)C(O)C4O)cc(O)c3C2=O)c5ccc(O)cc5)C(O)C(O)C1O ZMGSKTZDVIZXJS-UHFFFAOYSA-N 0.000 description 1
- PUPKKEQDLNREIM-QNSQPKOQSA-N kaempferol 3,7-di-O-alpha-L-rhamnoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=CC(O)=C2C(=O)C(O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=C(C=3C=CC(O)=CC=3)OC2=C1 PUPKKEQDLNREIM-QNSQPKOQSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000000055 matairesinol Nutrition 0.000 description 1
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 description 1
- 239000004750 melt-blown nonwoven Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- JPTOCTSNXXKSSN-UHFFFAOYSA-N methylheptenone Chemical compound CCCC=CC(=O)CC JPTOCTSNXXKSSN-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000001150 spermicidal effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- ROCZYNYGPDAYRQ-QGYXGAFPSA-N stigmasterol d-glucoside Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5C)C(C)C ROCZYNYGPDAYRQ-QGYXGAFPSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BKUSDHRTBIFINS-UHFFFAOYSA-N taraxasteryl acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4CCC5(C)CCC(C)(C)CC5C4(C)CCC23)C1(C)C BKUSDHRTBIFINS-UHFFFAOYSA-N 0.000 description 1
- YMBFCQPIMVLNIU-UHFFFAOYSA-N trans-alpha-bergamotene Natural products C1C2C(CCC=C(C)C)(C)C1CC=C2C YMBFCQPIMVLNIU-UHFFFAOYSA-N 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-PMTKVOBESA-N β-glycyrrhetinic acid Chemical compound C([C@@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-PMTKVOBESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Textile Engineering (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides traditional Chinese medicine essential oil, wherein the traditional Chinese medicine essential oil comprises one or more of the following traditional Chinese medicine extracts: clove, cinnamon, curcuma zedoary, perilla leaf, magnolia flower, citronella, common cnidium fruit, eupatorium, liquorice, honeysuckle, forsythia, dandelion and radix bupleuri, and application of the traditional Chinese medicine essential oil in preparing a preparation for preventing coronavirus infection and/or bacterial infection. The invention provides a method for inhibiting coronavirus and/or bacteria, which comprises the step of contacting the traditional Chinese medicine essential oil with the coronavirus and/or the bacteria. In addition, the invention also provides a daily necessity containing the traditional Chinese medicine essential oil.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to traditional Chinese medicine essential oil, application thereof in preparing a preparation for preventing coronavirus infection and/or bacterial infection, a method for inhibiting coronavirus and/or bacteria, and daily necessities containing the traditional Chinese medicine essential oil.
Background
Coronaviruses are a large family of viruses known to cause the common cold and more serious diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus is a new strain of coronavirus that has not been previously discovered in humans. Since 12 months in 2019, monitoring of influenza and related diseases is continuously carried out in Wuhan City in Hubei province, and multiple viral pneumonia cases are found and are diagnosed as viral pneumonia/lung infection. The international committee for virus classification states that this new pathogen will be named severe acute respiratory syndrome coronavirus No. 2 (severe acute respiratory syndrome coronavirus 2) or SARS-CoV-2, which is simply referred to as "new coronavirus" in the present invention.
Since the outbreak of the new coronavirus (SARS-CoV-2), a global pandemic was caused. Nearly 1500 million people are infected in the world by 7 middle ten days of 2020, and more than 60 people lose life, resulting in inestimable loss. After a person is infected with a new coronavirus (SARS-CoV-2), the common signs of the person include respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. At present, no specific treatment method exists for diseases caused by the new coronavirus (SARS-CoV-2), no specific antiviral medicine for the new coronavirus (SARS-CoV-2) exists, and no breakthrough progress exists in vaccine development.
Therefore, the discovery of a drug candidate for inhibiting the novel coronavirus (SARS-CoV-2) is imminent.
Disclosure of Invention
In view of the above, the present invention provides a traditional Chinese medicine essential oil and its use in preparation of a preparation for preventing coronavirus infection and/or bacterial infection, a method for inhibiting coronavirus and/or bacteria, and a daily necessity containing the traditional Chinese medicine essential oil.
According to a first aspect of the invention, the invention provides a traditional Chinese medicine essential oil, wherein the traditional Chinese medicine essential oil comprises one or more of the following traditional Chinese medicine extracts: clove, cinnamon, curcuma zedoary, perilla leaf, magnolia flower, citronella, fructus cnidii, eupatorium, liquorice, honeysuckle, fructus forsythiae, dandelion and radix bupleuri.
According to a second aspect of the present invention there is provided a method of inhibiting coronavirus and/or bacteria, said method comprising contacting an essential oil of a Chinese medicinal material according to the first aspect of the present invention with coronavirus and/or bacteria.
According to a third aspect of the present invention, there is provided the use of an essential oil of a Chinese medicinal material according to the first aspect of the present invention in the manufacture of a formulation for the prevention of coronavirus infection and/or bacterial infection.
According to a fourth aspect of the invention, the invention provides a daily necessity, which comprises the traditional Chinese medicine essential oil of the first aspect of the invention.
The invention has the beneficial effects that:
the invention uses the extracts of a plurality of Chinese medicinal materials to prepare the Chinese medicinal essential oil with the effects of resisting bacteria, viruses and the like, thereby being used for inhibiting coronavirus and/or bacteria and preventing and/or treating coronavirus infection and/or bacterial infection. The Chinese medicinal essential oil provided by the invention not only contains Chinese medicinal extracts, for example, through supercritical treatmentBoundary CO2The extract of Chinese medicinal materials obtained by extraction or steam distillation, and base oil commonly used in essential oil preparation, can not only give fragrant smell, but also have antibacterial and antiviral effects.
The traditional Chinese medicine essential oil is also applied to daily necessities such as masks, disinfectant, aromatherapy, spray, hand sanitizer or skin care products, has antibacterial and antiviral effects and aromatic taste, can make people happy, helps people prevent virus invasion, enhances the upper respiratory tract defense capacity, and simultaneously can keep physical and mental health of people.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art that other embodiments can be obtained according to the drawings without inventive labor.
FIG. 1 is a graphical representation of the results of the anti-neocoronaviruses (SARS-CoV-2) effect of low concentrations of essential oils (0.1% by volume) according to some embodiments of the invention;
FIG. 2 is a graphical representation of the results of the anti-neocoronaviruse (SARS-CoV-2) effect of high concentrations of essential oils (1% by volume) according to some embodiments of the invention;
FIG. 3 is a graphical representation of the results of antiviral effects of different concentrations of essential oils (0.003%, 0.01%, 0.1%, 0.3%, 1%, by volume percent) according to some embodiments of the present invention;
fig. 4 is a graph showing the results of antibacterial activities of five essential oils of clove, zedoary, cinnamon, bay leaf and citronella of example 3, wherein SA: staphylococcus aureus bacteria; EC: e.coli; KP: klebsiella pneumoniae; PA: pseudomonas aeruginosa; BS: b, bacillus subtilis; ah: aeromonas hydrophila; et: edwardsiella tarda; va: vibrio alginolyticus; and Vh: vibrio harveyi.
Fig. 5 is a schematic view showing an open structure of a mask according to some embodiments of the present invention, in which 1 denotes a metal wire, 2 denotes a medicated wire, 3 denotes an outer layer, 4 denotes a middle layer, and 5 denotes an inner layer.
Detailed Description
The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which embodiments of the invention are shown. It is to be understood that the described embodiments are merely a subset of the present invention and not all embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments disclosed herein are within the scope of the present invention.
The new coronavirus (SARS-CoV-2) has caused an infectious disease which is prevalent in the world, however, there is no specific treatment for the disease caused by the new coronavirus and no antiviral drug specific to the new coronavirus at present. Therefore, the discovery of candidate drugs capable of inhibiting coronavirus or further a novel coronavirus (SARS-CoV-2) is imminent.
The traditional Chinese medicine is a substance for preventing and treating diseases and having rehabilitation and health care functions under the guidance of the theory of traditional Chinese medicine, and is an important substance for preventing and treating diseases and resisting epidemic historically. The habit of inserting folium artemisiae argyi and wearing a fragrant bag at noon has been existed since ancient times, and the fragrant bag has the functions of resuscitation, dirt avoidance and epidemic avoidance. The Chinese herbs have several properties and actions to act on the disease condition, and many Chinese herbs have antibacterial and antiviral effects.
The essential oil is extracted from leaves, flowers, seeds, fruits, roots, barks, resins, hearts and other parts of plants by steam distillation, cold pressing, fat absorption and solvent extraction, and has high-concentration fragrance and volatility. The pure natural plant essential oil has fragrant smell, and after entering the brain, the natural aromatic essential oil can stimulate the anterior lobe of the brain to secrete two hormones, namely endorphin and enkephalin, so that the spirit is in a comfortable state, and the essential oil also has the effects of sterilizing, resisting inflammation, healing, deodorizing, tranquilizing, expelling parasites, softening and moistening the fine skin and the like. Although the chemical compositions of various essential oils are different, due to similar synthetic routes, a plurality of chemical components can be found in various plant essential oils, and the essential oils have the efficacies of sterilization, anti-inflammation and the like and also contain the chemical components with biological activity.
Based on the above, the invention uses the extracts of a plurality of Chinese medicinal materials to prepare the Chinese medicinal essential oil with antibacterial and antiviral effects, thereby being used for inhibiting coronavirus and/or bacteria and preventing and/or treating coronavirus infection and/or bacterial infection.
Thus, according to a first aspect of the present invention, there is provided a Chinese medicinal essential oil comprising one or more of the following extracts of Chinese herbs: clove, cinnamon, curcuma zedoary, perilla leaf, magnolia flower, citronella, fructus cnidii, eupatorium, liquorice, honeysuckle, fructus forsythiae, dandelion and radix bupleuri.
Flos Caryophylli, also known as Dingzi Xiang, Zhijixiang and flos Caryophylli. The bud of clove is a common traditional Chinese medicine. Modern researches show that the clove contains 15-20% of volatile oil, the main components in the oil comprise eugenol, beta-caryophyllene, acetyl eugenol and the like, and the oil also contains components of eugenol, acetyl eugenol, isoquercitin, kaempferol, quercetin, caryophyllene oxide, oleanolic acid, alpha-menthene and the like. Flos Caryophylli has stomach invigorating effect, and the leachate has obvious function of stimulating gastric secretion, and can relieve abdominal distention, nausea, emesis, etc. In addition, it has inhibitory effect on pathogenic fungi, coccus, streptococcus, and Bacillus such as pneumonia, dysentery, large intestine, typhoid fever, and influenza virus.
Cinnamon, also known as cinnamon, Cinnamomum cassia, is a dry bark of Cinnamomum cassia Presl, a plant of lauraceae. Cinnamon has a mild stimulation effect on intestines and stomach, can relieve gastrointestinal smooth muscle spasm, and has a strong anti-ulcer effect; can antagonize platelet aggregation, improve cardiovascular system, and regulate immunity; has tranquilizing, analgesic, antipyretic, and anticonvulsive effects on central nervous system; can be used for preventing and protecting yang deficiency and yin deficiency; has certain anti-inflammatory effect; has strong antifungal effect.
Rhizoma Curcumae, also known as Wen zedoary, rhizoma Curcumae, rhizoma Et radix Notopterygii, rhizoma Curcumae, rhizoma Zingiberis recens, and rhizoma Curcumae, mainly contains volatile oil, flavonoids, and terpenes. The Curcumae rhizoma mainly comprises curcumenone, curcumenol, Borneolum, radix et rhizoma Rhei cage for animals geranone, Camphora, curcumene, turmerone, curdione, cineole, daucosterol, beta-sitosterol, and palmitic acid. Curcumae rhizoma has effects of resisting tumor, resisting bacteria, increasing leukocyte, promoting blood circulation, and removing blood stasis; for the low-concentration tension and high-concentration relaxation of gastrointestinal smooth muscle; has liver protecting effect; improving acute renal failure; inhibiting platelet aggregation and antithrombotic formation; has anti-inflammatory effect.
Perilla leaf, also known as folium Perillae, thallus Porphyrae, and Su, contains perillaldehyde, perillaketone, perilla ketone, menthol, alpine baicalin, New Zealand vitexin II, and lukunin. Folium Perillae has tranquilizing and antipyretic effects; can inhibit the excitability membrane; can promote secretion of digestive juice and enhance gastrointestinal peristalsis; has the functions of relieving cough, eliminating phlegm and relieving asthma on the respiratory system and has the double functions of stopping bleeding and resisting coagulation on the blood system; increase blood glucose; regulating organism immunity, and resisting mutagenesis; has antimicrobial, broad-spectrum antibacterial, and antiinflammatory effects.
Flos Magnoliae, also called magnolia or magnolia liliiflora, contains volatile oil, the main component of the oil is 1, 8-cineole, etc., and the other components of beta-pinene, 1, 8-cineole, camphor, hederagenin, bergamotene, magnolia biondin A, etc., and has the functions of anesthesia, antianaphylaxis, anti-inflammation, blood pressure reduction, uterine excitation, anti-platelet aggregation, microorganism resistance, pain relief and microcirculation improvement.
The citronella, namely the lemongrass, the lemongrass and the lemongrass, the stem and leaf contain 0.4 to 0.8 percent of volatile oil, wherein the content of the citral serving as a main component is 75 to 85 percent, and a small amount of citronellal, geraniol and methyl heptenone are contained. The volatile oil of herba Cymbopogonis Citrari has antifungal effect (such as Streptomyces venezuelae). Has good effect of treating rheumatism, treating migraine, resisting infection, improving digestive function, deodorizing and expelling parasites. Resisting infection, astringing skin, and regulating greasy and unclean skin. It can give refreshing feeling and restore physical and mental balance (especially in early stage of disease recovery). Is essential oil with the most extensive application in aromatherapy and medical treatment. It can also be used as indoor aromatic.
Fructus Cnidii, also known as fructus Foeniculi, radix Dauci Sativae, flos Serpentis, SHEZHU, SHEXIAN, and fructus Cnidii. Contains volatile oil, which mainly comprises pinine, isovalerian borneol ester, parsley phenol methyl ether, dihydrocarveol, bergapten, cnidium lactone, isoanisic apigenin, etc. In addition, it contains components such as camphene, isoimperatorin, Columbia lactone, bornyl acetate, limonene, 3-sitosterol, etc. Fructus Cnidii has effect in resisting arrhythmia; inhibiting the heart; lowering blood pressure; a sex hormone-like effect; antifungal, insecticidal, trichomonal and spermicidal; dispel phlegm and relieve dyspnea; local anesthesia; anti-allergic reaction, anti-mutagenic effect; delaying aging; affecting the metabolism of plasma prostacyclin and inner cyclic nucleotides; inhibiting smooth muscle contraction; preventing and treating osteoporosis; has sedative and hypnotic effects.
Herba Eupatorii, herba Lycopi, herba Eupatorii, and herba Eupatorii chinensis containing volatile oil; the leaf contains coumarin, coumaric acid, and thymoquinol; the root contains vanillin. And other components such as aurantiol acetate, thymol methyl ether, p-cymene, taraxasterol acetate, and 3-sitosterol. Herba Eupatorii has expectorant, antiviral, and anticancer effects; has inhibitory effect on influenza virus; and can inhibit ovulation.
Licorice, also known as sweet licorice, licorice root, aged people and Mexican grass, mainly contains liquiritin, glycyrrhizic acid, glycyrrhizin, syringene oxide, glycyrrhetinic alcohol, 18 a-hydroxy glycyrrhetinic acid, isoglycyrrhetinic acid, glycyrrhizin, formononetin, neolicochalcone D, glabrene aglycone, isolicoflavonol, triterpenoid saponin, coumarin and other components. The licorice has the functions of adrenocortical hormone, anti-inflammation, anti-ulcer, anti-anaphylaxis, anti-cancer, anti-bacteria, anti-virus, promoting pancreatic secretion, inhibiting isolated intestine, regulating immunity, relieving cough, eliminating phlegm, resisting mutation, detoxifying, resisting oxidation, protecting the functions of ear and vestibule, promoting urination, protecting liver, preventing arteriosclerosis, resisting cerebral ischemia, preventing diabetic complications and the like.
Flos Lonicerae, also known as Lonicera Japonica flos, flos Lonicerae, diurea, flos Lonicerae, flos Celosiae Cristatae, and radix Ampelopsis Brevipedunculatae, and contains luteolin, inositol 1%, volatile oil, terpenes, and phenolic acid. The beverage contains chlorogenic acid, isochlorogenic acid, ginkgol, beta-sitosterol, stigmasterol-D-glucoside, etc. The flos Lonicerae has effects of resisting pathogenic microorganism, resisting virus, resisting inflammation, relieving fever, promoting phagocytic function of inflammatory cell, reducing blood lipid, exciting central nervous system, resisting fertility, preventing gastric ulcer, and exciting uterus. The decoction, water extract and purified liquid of honeysuckle flower have good killing and inhibiting effects on the streptococcus mutans causing dental caries by using a plate punching method, and the bacteriostatic effect is obviously enhanced along with the increase of the concentration.
Fructus forsythiae, also known as fructus forsythiae, HUANGHUATIAO, HUANGLIHUA, contains lignans, flavonoids, volatile components, phenethyls, ethyl cyclohexanol, triterpenes, and coumarins. Also comprises betulinic acid, phillyrin, arctiin, matairesinol, pinoresinol, phillyrin C, phillyrin D, etc. Fructus forsythiae has antimicrobial effect; inhibiting phosphodiesterase, lipoxygenase; stopping vomiting; anti-liver damage; anti-inflammatory; inhibiting elastase activity; reduce spontaneous hypertension, etc.
Herba Taraxaci, also called herba Taraxaci, herba Violae, herba Taraxaci, flos Hostae Plantagineae, flos Tagetis Erectae, herba Commelinae, flos Canarii albi, and herba Violae contains taraxasterol, choline, inulin, pectin, taraxasterol, taraxacin, and caffeic acid. Has effects in resisting pathogenic microorganism, resisting tumor, resisting gastric ulcer, promoting function of gallbladder, protecting liver, directly exciting heart of frog in vitro at low concentration, and inhibiting at high concentration. Can improve the tension of isolated duodenum and strengthen the contractility thereof, and is clinically considered to have the functions of strengthening stomach and laxation. The injection has strong bactericidal effect on staphylococcus aureus resistant strains and hemolytic streptococcus in a test tube, and also has a certain bactericidal effect on pneumococcus, meningococcus, diphtheria bacillus, pseudomonas aeruginosa, proteus, dysentery bacillus, typhoid bacillus and catacoccus.
Radix bupleuri, also known as bupleurum falcatum, bupleurum nanum, ground smoke, peruvian, mountain vegetable, rue grass and firewood, mainly contains valeric acid, linolenic acid, palmitic acid, stearic acid, kaempferol, kaempferitrin, quercetin, rutin, myrcene, borneol, saikosaponin II, myrtenol, alpha-spinasterol, deglucosyl saikosaponin alpha, saikosaponin and other components. And contains other components such as Chunfoushou alcohol. Pharmacological tests prove that the bupleurum has the effects of resisting inflammation, relieving fever, tranquilizing, relieving pain, relieving cough and resisting convulsion; can relieve liver injury and promote bile secretion; has effects in lowering blood pressure, reducing serum cholesterol, and promoting hemolysis; has antiulcer, antibacterial, antiviral, antitumor, blood sugar increasing, blood fat content reducing, and radiation injury resisting effects.
In a further embodiment, the extract of the chinese traditional medicine is extracted by supercritical CO2Extracting with extraction method or steam distillation method.
Thus, in the present invention, "extract" means, for example, by using supercritical CO2Extracting Chinese medicinal materials such as flos Caryophylli, cortex Cinnamomi, Curcumae rhizoma, folium Perillae, and flos Magnoliae by extraction or steam distillation to obtain extract containing low-polarity and volatile small molecule components. Of course, other methods generally used for extracting Chinese herbs known in the art may be used, and the present invention is not limited thereto.
Supercritical CO2The extraction method comprises contacting supercritical fluid with substance to be separated under supercritical state to selectively extract polar components, boiling point components and molecular weight components sequentially. The method comprises pulverizing Chinese medicinal materials, adding into an extractor, adding a small amount of polar solvent (carrying agent) into the extractor, and allowing CO to flow at room temperature and low pressure (20-30 deg.C, 100-200bar)2Supercritical fluid reaches subcritical fluid state, fluid is injected into the extractor from bottom to top to enter an extraction stage, after extraction is completed, extract liquor is decompressed and then enters a first separator and a second separator in sequence, and traditional Chinese medicine extract is collected at the bottom of the second separator.
Steam distillation is an extraction method in which a plant material containing volatile components is co-distilled with water to distill off the volatile components along with the steam, and the volatile components are separated by condensation. The crushed Chinese medicine is set inside a distiller with cooler connected to the upper part and steam connected to the lower part to maintain the steam pressure of 0.12-0.13 MPa. Vapor permeates the medicinal powder, volatile components in the medicinal powder are gasified due to the high temperature of the vapor, the vapor enters a cooler along with water vapor from a distillation tube, the vapor and the gasified volatile components are cooled in the cooler to form an oil-water mixture, the oil-water mixture is collected at the outlet of the cooler by an oil-water separator, after standing, oil and water are automatically separated, the upper layer is the traditional Chinese medicine extract, and the lower layer is water. Removing water from the lower layer with a separator to obtain the desired Chinese medicinal extract.
The Chinese medicinal essential oil may comprise extract of one Chinese medicinal material, or may comprise combination of extracts of multiple Chinese medicinal materials (such as two, three, four, five, six, seven, eight, nine, ten, eleven and twelve). It is understood that the herbal extracts can be combined in any ratio, and can be adjusted accordingly based on taste preferences of different people.
In one embodiment, the herbal essential oil comprises a combination of herbal extracts of: zedoary extract + cinnamon extract, bupleurum extract + cinnamon extract, licorice extract + clove extract, or eupatorium extract + bupleurum extract. Further, the zedoary extract + cinnamon extract, the bupleurum extract + cinnamon extract, the glycyrrhiza extract + clove extract or the eupatorium extract + bupleurum extract are combined in the ratio of (1-5): 5-1, for example, in the ratio of 1:5, 1:3, 1:2, 2:3, 1:1, 2:1, 3:1, 4:1, 5:1, preferably in the ratio of 1: 1.
As is well known to those skilled in the art, pure essential oils are very irritating, can cause damage when rubbed directly on the skin, and are very harmful, so the essential oil must be diluted before use on the skin. The base oil is a non-volatile oil extracted from seeds, flowers, rhizomes or fruits of plants, can lubricate the skin, can be directly used for skin massage, and is usually used for diluting simple essential oil (pure essential oil). The base oil can reduce irritation to skin and respiratory mucosa, slow down volatilization of essential oil, and prolong service life.
Thus, in one embodiment, the essential oil of Chinese traditional medicine further comprises one, two or three of sweet almond oil, rose seed oil or grape seed oil as a base oil. Preferably, the traditional Chinese medicine essential oil comprises grape seed oil. The grape seed oil has clear color and light taste, and can be suitable for different skins. Of course, other base oils known in the art may also be used.
In one embodiment, the concentration of each of the extracts in the herbal essential oils is 0.003% to 10% by volume, e.g., 0.005%, 0.008%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%, or any number between any two of these ranges.
In one embodiment, the concentration of each of the extracts in the herbal essential oil is 0.1% to 10%, for example 0.1% to 1%, by volume percentage.
According to a second aspect of the present invention there is provided a method of inhibiting coronavirus and/or bacteria, said method comprising contacting an essential oil of a Chinese medicinal material according to the first aspect of the present invention with coronavirus and/or bacteria.
In the present invention, the method may be a method for non-therapeutic purposes, for inhibiting, for example, coronavirus and/or bacteria in the ambient air, on the surface of an object, etc.; the method may also be a method for therapeutic purposes, e.g. for a human or animal subject.
"coronavirus" refers to a virus having a corona process on its envelope that is shaped like coronas. Coronavirus particles are irregular in shape and about 60-220nm in diameter. The virion is surrounded by a fat membrane, the surface of which has three glycoproteins: spike Protein (S, Spike Protein, which is the receptor binding site, cytolytic and major antigenic site); envelope proteins (E, Envelope Protein, smaller, Envelope-binding proteins); membrane proteins (M, Membrane Protein, responsible for transmembrane transport of nutrients, budding release of nascent viruses and formation of viral envelope).
The traditional Chinese medicine essential oil can reduce the combination of spike protein and angiotensin converting enzyme 2(ACE2) by reducing the spike protein of coronavirus, thereby playing a role in inhibiting coronavirus. Thus, in one embodiment, the essential oil of Chinese herbs inhibits coronavirus by reducing spike protein of coronavirus coat.
In some embodiments, the coronavirus is severe acute respiratory syndrome coronavirus No. 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), or bat SARS-like coronavirus (bat-SL-CoVZC 45).
In some embodiments, the bacteria are one or more of Staphylococcus aureus (Staphylococcus aureus), Escherichia coli (Escherichia coli), Pseudomonas aeruginosa (Pseudomonas aeruginosa), Klebsiella pneumoniae (Klebsiella pneumoniae), Bacillus Subtilis (BS), Aeromonas hydrophila (Aeromonas hydrophylla), Edwardsiella tarda (edwards tarda), Vibrio alginolyticus (Vibrio alginolyticus), Vibrio harveyi (Vibrio harveyi).
According to a third aspect of the invention, the invention also provides the use of the essential oil of the traditional Chinese medicine of the first aspect of the invention in the preparation of a preparation for preventing coronavirus infection and/or bacterial infection.
In some embodiments, the coronavirus is severe acute respiratory syndrome coronavirus No. 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), or bat SARS-like coronavirus (bat-SL-CoVZC 45).
In some embodiments, the bacteria is one or more of staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, klebsiella pneumoniae, bacillus subtilis, aeromonas hydrophila, edwardsiella tarda, vibrio alginolyticus, and vibrio harveyi.
According to a fourth aspect of the invention, the invention provides a daily necessity, which comprises the traditional Chinese medicine essential oil of the first aspect of the invention.
In some embodiments, the article of daily use is a mask, a disinfectant, an aromatherapy, a spray, a hand sanitizer, or a skin care product.
In some embodiments, the daily necessities are masks, and the herbal essential oil is present in the masks in the form of medicated thread.
In some embodiments, the concentration of each of the extracts in the herbal essential oils is 5% to 10%, e.g., 5%, 6%, 7%, 8%, 9%, or 10%, or any number in a range of any two of them.
In some embodiments, the mask is a disposable mask comprising a left band, an outer layer as a water barrier layer, a middle layer as a filter layer, an inner layer as a water absorbing layer, a metal strip for clamping the bridge of the nose, and a right band, and the medicated thread is located between the outer layer and the middle layer, e.g., below the metal strip, e.g., 0.5-2 cm below.
In one embodiment, the medicated thread is located between the outer layer and the middle layer and below the metal strip.
In one embodiment, the medicated thread is located 0.5-2 centimeters below the metal strip, such as 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 centimeters below or any distance therebetween.
As is generally understood by those skilled in the art, the left and right straps are primarily for the purpose of wear. The outer layer is mainly used for waterproof, the material is non-woven fabric, and the non-woven fabric has a water-repelling function and can prevent spray and large-particle dust. The middle layer is mainly used for filtering, the material is melt-blown non-woven fabric, and bacteria and particles can be filtered through the melt-blown netting technology. The inner layer is mainly used for absorbing water, is made of non-woven fabric, and is subjected to surface hydrophilic treatment, so that the contact part of the skin is comfortable. The metal strip in the mask is used for clamping the nose bridge, and the material of the metal strip can be aluminum, an environment-friendly plastic strip and the like. The medicated thread is any material with adsorption effect soaked with Chinese medicinal essential oil, such as cotton thread, non-woven thread, cotton sliver or non-woven fabric strip. Further, the length of the medicated thread may be adjusted according to the mask, for example, 17 cm. When the mask is manufactured, the material with adsorption effect is added into the essential oil of traditional Chinese medicine by soaking method to prepare medicated thread, and then the medicated thread is put into a production machine, so that the medicated thread is placed in the mask. Of course, any material known in the art that is commonly used for the above-described corresponding structures of the mask may be used in the present invention, and is not further limited herein.
In the present invention, the mask may be any mask known in the art, and may be a medical mask or a non-medical mask, and may be, for example, an N95 type mask, a medical surgical mask, or the like. Therefore, the medicated thread can be placed at a suitable position according to the present invention according to different mask types.
In the invention, the essential oil is absorbed by soaking the material with adsorption in the traditional Chinese medicine essential oil, and then the medicated thread containing the essential oil is added between the outer waterproof layer and the middle filter layer, preferably at the position below the metal strip, so that on one hand, the medicated thread containing the traditional Chinese medicine essential oil can be prevented from directly contacting the waterproof layer and the filter layer, the effect of the mask on blocking bacteria and viruses can not be influenced, and on the other hand, the medicated thread containing the traditional Chinese medicine essential oil is added in the mask instead of on the surface of the mask, and the medicated thread can be prevented from falling off and losing the effect. In addition, the added medicated thread can be suitable for a full-automatic mask production line.
The invention has the beneficial effects that:
the invention uses the extracts of a plurality of Chinese medicinal materials to prepare the Chinese medicinal essential oil with the effects of resisting bacteria, viruses and the like, thereby being used for inhibiting coronavirus and/or bacteria and preventing and/or treating coronavirus infection and/or bacterial infection. The essential oil of Chinese traditional medicine provided by the invention not only contains the extract of Chinese traditional medicine, for example, by supercritical CO2The extract of Chinese medicinal materials obtained by extraction or steam distillation, and base oil commonly used in essential oil preparation, can not only give fragrant smell, but also have antibacterial and antiviral effects.
The traditional Chinese medicine essential oil is also applied to daily necessities such as masks, disinfectant, aromatherapy, spray, hand sanitizer or skin care products, has antibacterial and antiviral effects and aromatic taste, can make people happy, and can keep physical and mental health while helping people prevent virus invasion and enhancing upper respiratory tract defense capacity.
The invention applies the traditional Chinese medicine essential oil to the mask in the form of the medicated thread, the medicated thread is prepared by soaking a material with adsorption in the traditional Chinese medicine essential oil, and then the medicated thread is placed between the outer waterproof layer and the middle filtering layer, preferably, the mask is prepared at the position below the metal strip, so that on one hand, the traditional Chinese medicine essential oil can be prevented from directly contacting the waterproof layer and the filtering layer, the effect of blocking bacteria and viruses of the mask can not be influenced, on the other hand, the medicated thread containing the traditional Chinese medicine essential oil is placed in the mask instead of on the surface of the mask, and the effect loss of the medicated thread due to the falling can also be avoided. The mask provided by the invention not only adds various fragrant and fresh smells to the mask, but also has the functions of refreshing, resuscitation, antibiosis, antivirus and the like by adding the medicated thread containing the traditional Chinese medicine essential oil into different layers of the mask on the premise of not damaging the waterproof layer structure of the mask. The mask provided by the invention is simple to manufacture, low in cost, convenient to use and easy to popularize, and the medicated thread added in the mask is also suitable for a full-automatic mask production line.
The present invention will now be described more specifically and in detail with reference to the accompanying drawings and examples, which are only preferred embodiments of the invention and are not intended to limit the invention. All the raw materials and reagents of the invention are conventional market raw materials and reagents unless otherwise specified.
Example 1: preparation method of traditional Chinese medicine essential oil
Preparation of Chinese medicine extract
1. Supercritical CO2Extraction method
Pulverizing Chinese medicinal materials, adding into an extractor, adding a small amount of polar solvent (carrying agent) into the extractor, and allowing CO to flow at room temperature and low pressure (20-30 deg.C, 100-2Supercritical fluid reaches subcritical fluid state, fluid is injected into the extractor from bottom to top to enter an extraction stage, after extraction is completed, extract liquor is decompressed and then enters a first separator and a second separator in sequence, and traditional Chinese medicine extract is collected at the bottom of the second separator.
2. Steam distillation process
Placing the pulverized Chinese medicinal materials into a distiller, connecting a cooler at the upper part, and introducing steam at the lower part to maintain the steam pressure of 0.12-0.13 MPa. Vapor permeates the medicinal powder, volatile components in the medicinal powder are gasified due to the high temperature of the vapor, the vapor enters a cooler along with water vapor from a distillation tube, the vapor and the gasified volatile components are cooled in the cooler to form an oil-water mixture, the oil-water mixture is collected at the outlet of the cooler by an oil-water separator, after standing, oil and water are automatically separated, the upper layer is the traditional Chinese medicine extract, and the lower layer is water. Removing water from the lower layer with a separator to obtain the desired Chinese medicinal extract.
Second, preparation of Chinese medicine essential oil
In the following examples supercritical CO will be passed2Mixing the Chinese medicinal extract and base oil at required ratio to obtain Chinese medicinal essential oil.
Example 2: research on the action against the New coronavirus (SARS-CoV-2) (first experimental principle):
the antiviral efficacy of the herbal extract was demonstrated by examining the inhibition of Spike protein (Spike protein) present in the capsid of the New coronavirus (SARS-CoV-2) by the herbal extract samples. When the spike protein is inhibited by herbal extracts, its binding to the human receptor angiotensin converting enzyme 2(ACE2) is reduced. The less the spike protein binds to ACE2, the stronger the Chinese medicinal extract has the effect of inhibiting the spike protein. The method is an effective in vitro detection means for testing the efficacy of the medicine for resisting the new coronavirus (SARS-CoV-2).
(II) Experimental materials:
the used traditional Chinese medicine essential oil comprises the following components: clove, eupatorium, sandalwood, cablin potchouli herb, zedoary, honeysuckle, folium artemisiae argyi, cinnamon, fructus forsythiae, liquorice, dandelion, perilla leaf, bay leaf, rhizoma atractylodis, radix bupleuri, nutmeg, magnolia flower, citronella, houttuynia cordata, fructus cnidii and the like; SARS-CoV-2Spike ACE2 Inhibitor Screening Assay Kit (from BPS Bioscience) was tested against the New coronaviruses (SARS-CoV-2).
(III) experiment steps:
the spike protein solution at a concentration of 1. mu.g/mL was added to a specially prepared 96-well plate at 50. mu.L per well and incubated overnight at 4 ℃. After incubation was complete, the supernatant was decanted and washed 3 times with 100 μ L of blocking solution a. The solution was patted dry, 100. mu.L of blocking solution B was added to each well, and the mixture was shaken at room temperature for 1 hour. After the solution was patted dry, 20. mu.L of blocking solution A was added to each well, 10. mu.L of 5% DMSO aqueous solution was added to each of the positive control well and the negative control well, 10. mu.L of sample solution (containing 5% DMSO) was added to each of the sample wells, and the mixture was shaken at room temperature for 1 hour. Then, 20 μ L of blocking solution a was added to the positive control wells, the highest inhibition rate of the simulation experiment was performed by adding blocking solution a containing no ACE2-His to the positive control wells, 20 μ L of ACE2-His solution with a concentration of 2.5ng/μ L was added to the negative control wells and the sample wells, and the reaction was performed with shaking at room temperature for 1 hour. After completion of the reaction, the liquid was patted dry and washed 3 times with 100. mu.L of blocking solution A. The solution was patted dry, 100. mu.L of blocking solution B was added to each well, and the mixture was incubated at room temperature for 10 minutes. After the incubation, the liquid was patted dry, 10. mu.L of Anti-His-HRP solution was added to each well, and the mixture was incubated at room temperature with shaking for 1 hour. The cells were washed 3 times with 100. mu.L of blocking solution A, and then 100. mu.L of blocking solution B was added to each well, followed by incubation at room temperature for 10 minutes. Finally, the liquid was patted dry and a mixture of 100. mu. L ELISA ECL substrate A and B (1:1) was added to each well to measure the intensity of chemiluminescence. Data were statistically analyzed with SPSS 22 and significance was expressed as p <0.05 and p < 0.01.
(IV) experimental results:
as shown in fig. 1 and 2, both the low concentration Chinese medicinal essential oil (0.1% by volume) and the high concentration Chinese medicinal essential oil (1% by volume) have an effect of resisting new crown virus (SARS-CoV-2), and the antiviral effects of clove, eupatorium, curcuma zedoary, honeysuckle, cinnamon, forsythia, licorice, dandelion, perilla leaf, bupleurum, magnolia flower, citronella and cnidium fruit are significant. Specifically, the inhibition effect of the low-concentration Chinese medicinal essential oil of eupatorium, honeysuckle, dandelion, houttuynia cordata and fructus cnidii on the combination of the spike protein and the ACE2 is over 90%, wherein the inhibition effect of the eupatorium, the dandelion, the houttuynia cordata and the fructus cnidii on the combination of the spike protein and the ACE2 can almost reach 100% (figure 1), and the inhibition effect of the high-concentration Chinese medicinal essential oil of clove, eupatorium, honeysuckle, liquorice, dandelion, perilla leaf, radix bupleuri and fructus cnidii on the combination of the spike protein and the ACE2 can almost reach 100% (figure 2). In FIGS. 1 and 2, positive controls were 5% DMSO in water and ACE 2-His-free solutions; negative controls were 5% DMSO in water and 2.5 ng/. mu.L ACE2-His in water.
Of these essential oils, we further selected the essential oils of clove, eupatorium, honeysuckle and cinnamon with significant antiviral activity, and measured their anti-new crown virus (SARS-CoV-2) activities at concentrations of 0.003%, 0.01%, 0.03%, 0.1%, 0.3% and 1% (by volume), and the results are shown in fig. 3. As can be seen from FIG. 3, at a concentration of 0.003%, the clove, eupatorium, honeysuckle and cinnamon essential oil also show antiviral ability, and the antiviral activity is in direct proportion to the concentration.
(V) preliminary conclusion:
screening 20 Chinese medicinal extracts for resisting new crown virus (SARS-CoV-2), and finding that the three Chinese medicinal extracts have insignificant antiviral effects, and seventeen extracts have good antiviral effects, wherein the Chinese medicinal essential oils of clove, herba Eupatorii, rhizoma Curcumae, flos Lonicerae, cortex Cinnamomi, fructus forsythiae, radix Glycyrrhizae, herba Taraxaci, folium Perillae, radix bupleuri, flos Magnoliae, herba Cymbopogonis Citrari, fructus Cnidii, etc. all have better effect of resisting new crown virus (SARS-CoV-2). The inhibition effect of patchouli, sandalwood and atractylodes rhizome oil on S protein is not obvious.
Example 3: antibacterial action of Chinese medicinal essential oil (I) experimental strain:
including 5 common airborne pathogens: staphylococcus Aureus (SA); escherichia Coli (EC); pseudomonas Aeruginosa (PA); klebsiella Pneumoniae (KP); bacillus Subtilis (BS), and 4 common aquaculture common pathogens: aeromonas hydrophila (Ah); edwardsiella tarda (edwards siella tarda, Et); vibrio algicidal (Vibrio algicidalicus, Va); vibrio harveyi (Vibrio harveyi, Vh). All bacteria were purchased from the Guangdong province Collection of microorganisms.
(II) culture medium:
5 kinds of aerogenic pathogenic bacteria (SA, EC, PA, KP and BS), Ah and Et were cultured in LB medium at 37 ℃; va and Vh were cultured at 30 ℃ in 2216E medium.
(III) Experimental method:
and (3) determining the antibacterial activity of the extract sample by adopting a filter paper sheet method, and testing the size of the inhibition zone of the sample on bacteria.
(IV) experimental steps:
SA, EC, PA, KP, BS, Ah and Et were prepared in 100. mu.L of 1X 105Respectively coating the CFU/mL suspension on LB agar culture medium; va and Vh were prepared as 1X 10 in 100. mu.L5CFU/mL suspension was spread on 2216E agar medium, respectively. Placing filter paper sheets (diameter 6mm) soaked with 20 kinds of Chinese medicinal essential oil on the surface of the culture medium respectively, allowing the filter paper sheets to cling to the surface of the culture medium, standing for 30 minutes, placing in an incubator, culturing under appropriate conditions for 24 hours, and measuring the diameter of the transparent antibacterial ring. Because the traditional Chinese medicine essential oil is in spherical diffusion in the culture medium, the concentration of the traditional Chinese medicine essential oil is decreased from inside to outside, the diameter of the formed transparent ring is in positive correlation with the antibacterial activity.
(V) experimental results:
the 20 kinds of Chinese medicinal essential oil have different growth inhibition effects on nine kinds of bacteria, wherein the cinnamon extract has the most remarkable antibacterial activity which is stronger than that of a positive control kanamycin (5 mg/mL). Specific antimicrobial activities are shown in table 1.
TABLE 1 antibacterial Activity results of twenty Chinese medicinal essential oils
Note: and SA: staphylococcus aureus bacteria; EC: e.coli; KP: klebsiella pneumoniae; PA: pseudomonas aeruginosa; BS: b, bacillus subtilis; ah: aeromonas hydrophila; et: edwardsiella tarda; va: vibrio alginolyticus; and Vh: vibrio harveyi
(VI) preliminary conclusion:
the results of the antibacterial experiments in table 1 show that the extracts of cinnamon, clove and bay leaf have better inhibition effect on 9 bacteria; the citronella extract shows better inhibitory activity to 8 bacteria; the curcuma zedoary extract also shows relatively good bacteriostatic efficacy on 5 bacteria, wherein the cinnamon extract has the most remarkable activity, and the inhibitory activity on seven bacteria is stronger than that of a positive control kanamycin (5 mg/mL).
The inhibitory effects of cinnamon, clove, zedoary, bay leaf and citronella on various bacteria are shown in fig. 4.
Example 4: determination of skin irritation and sensitivity of Chinese medicinal essential oil
Skin sensitivity test: 12 volunteer subjects (5 male and 7 female, 22-45 years old) were treated by diluting the essential oil (grape seed oil as base oil) to 5% (by volume), applying to the inner side of the left arm of the subject, and recording whether there was any sensitive reaction such as redness and itching after 1 hr. The observation results show that: the skin sensitivity phenomena such as red swelling, itching, desquamation, eczema and the like do not appear.
Example 5: manufacture of antiviral essential oil mask
According to the skin test of example 4, no allergic result was found, and we diluted the essential oil of chinese traditional medicine with grape seed oil to 5% (volume ratio), thereby preparing the essential oil of chinese traditional medicine ready for use. Then, the antiviral essential oil mask of the present invention is further manufactured on the basis of a general mask.
The first method is as follows: adding 10 mu L of instant Chinese medicinal essential oil into the non-woven cotton stuck with double-sided adhesive tape until the essential oil is completely adsorbed, and sticking the essential oil on the bottommost part of the back surface of the disposable mask, thereby preparing the antiviral essential oil mask.
The second method comprises the following steps: the medicated thread 2 is obtained by impregnating cotton thread, cotton sliver or non-woven fabric strip having adsorption function with the essential oil of the Chinese medicinal materials of the present invention, and then fixed at an upper position between the outer layer 3 (i.e., waterproof layer) and the middle layer 4 (i.e., filter layer) of the disposable mask, for example, at about 1 cm below the metal thread 1 sandwiching the bridge of the nose, to facilitate nasal mucosa absorption (fig. 5). Another antiviral essential oil mask of the present invention was obtained in the above manner.
It should be noted that it is not desirable to add essential oil directly to the waterproof layer of the mask because the essential oil molecules can damage the water layer and the electrostatic filter layer, rendering the mask ineffective. In addition, the structural configuration can avoid direct contact with the waterproof layer and the filter layer, and does not influence the effect of the mask on blocking viruses and bacteria; in addition, the medicated thread is placed in the mouth cover instead of on the surface, so that the medicated thread can be prevented from falling off and losing efficacy.
Example 6: application of antiviral essential oil mask
14-20 volunteer subjects were assigned to prevent inhalation of new coronaviruses. Mask and questionnaire survey with different essential oils of Chinese medicinal materials are distributed every day. The statistical results are shown in table 2 below, and table 3 shows the contents of the questionnaire: gender, age, wearing time, smell, taste duration, satisfaction, discomfort to the eyes, nose and skin of a human, etc.
TABLE 2 questionnaire statistics after wearing disposable mask with essential oils of traditional Chinese medicine
TABLE 3 questionnaire details of eight Chinese medicinal essential oils
And (4) conclusion: as shown by the statistical results in tables 2 and 3, the most satisfactory essential oil of Chinese traditional medicine is Eupatorium. Additionally, cinnamon oil and bupleurum oil are combined in a 1:1 ratio; and clove oil and licorice oil and eupatorium oil and bupleurum oil in a 1:1 combination, all gave better satisfaction in questionnaires.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (18)
1. A traditional Chinese medicine essential oil, wherein the traditional Chinese medicine essential oil comprises one or more of the following traditional Chinese medicine extracts: clove, cinnamon, curcuma zedoary, perilla leaf, magnolia flower, citronella, fructus cnidii, eupatorium, liquorice, honeysuckle, fructus forsythiae, dandelion and radix bupleuri.
2. The essential oil of Chinese herbs of claim 1, wherein the extract of Chinese herbs is extracted by supercritical CO2Extracting with extraction method or steam distillation method.
3. The herbal essential oil of claim 1 or 2, wherein the herbal essential oil comprises a combination of the following herbal extracts: zedoary extract + cinnamon extract, bupleurum extract + cinnamon extract, licorice extract + clove extract, or eupatorium extract + bupleurum extract.
4. The essential oil of any one of claims 1 to 3, further comprising one or more of sweet almond oil, rose seed oil or grape seed oil as a base oil.
5. The herbal essential oil according to any one of claims 1 to 4, wherein the concentration of each extract in the herbal essential oil is between 0.003% and 10% by volume.
6. The traditional Chinese medicine essential oil according to claim 5, wherein the concentration of each extract in the traditional Chinese medicine essential oil is 0.1-10% by volume percentage.
7. A method for inhibiting coronavirus and/or bacteria, said method comprising contacting an essential oil of a Chinese medicinal material according to any one of claims 1 to 6 with coronavirus and/or bacteria.
8. The method of claim 7, wherein the coronavirus is severe acute respiratory syndrome coronavirus No. 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), or bats SARS-like coronavirus (bat-SL-CoVZC 45).
9. The method of claim 7, wherein the bacteria is one or more of Staphylococcus aureus (Staphyloccus aureus), Escherichia coli (Escherichia coli), Pseudomonas aeruginosa (Pseudomonas aeruginosa), Klebsiella pneumoniae (Klebsiella pneumoniae), Bacillus Subtilis (BS), Aeromonas hydrophila (Aeromonas hydrophylla), Edwardsiella tarda (Edwardsiella tarda), Vibrio alginolyticus (Vibrio algirylicus), and Vibrio harveyi (Vibrio harveyi).
10. The method of any one of claims 7-9, wherein the chinese medicinal essential oil inhibits coronavirus by reducing spike protein of coronavirus coat.
11. Use of the essential oil of a Chinese medicinal material according to any one of claims 1 to 6 in the manufacture of a formulation for the prevention of coronavirus infection and/or bacterial infection.
12. The use of claim 11, wherein the coronavirus is severe acute respiratory syndrome coronavirus No. 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), middle east respiratory syndrome coronavirus (MERS-CoV), or bats SARS-like coronavirus (bat-SL-CoVZC 45).
13. The use according to claim 11, wherein the bacteria is one or more of staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, klebsiella pneumoniae, bacillus subtilis, aeromonas hydrophila, edwardsiella tarda, vibrio alginolyticus, and vibrio harveyi.
14. A daily necessity comprising the essential oil of the Chinese medicine according to any one of claims 1 to 6.
15. The daily necessity of claim 14, wherein the daily necessity is a mask, a disinfectant, an aromatherapy, a spray, a hand sanitizer, or a skin care product.
16. The daily necessity according to claim 15, wherein the daily necessity is a mask, and the essential oil of the chinese medicine is present in the mask in the form of medicated thread.
17. The daily item of claim 16, wherein the concentration of each of the extracts in the herbal essential oils is 5% -10%, such as 5%, 6%, 7%, 8%, 9% or 10%.
18. A commodity according to claim 16 or 17, wherein the mask is a disposable mask comprising a left band, an outer layer as a waterproof layer, a middle layer as a filter layer, an inner layer as a water absorbing layer, a metal strip for clamping the bridge of the nose and a right band, and the medicated thread is located between the outer layer and the middle layer, such as below the metal strip, such as 0.5-2 cm below.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011002501.5A CN114246925A (en) | 2020-09-22 | 2020-09-22 | Traditional Chinese medicine essential oil and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011002501.5A CN114246925A (en) | 2020-09-22 | 2020-09-22 | Traditional Chinese medicine essential oil and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114246925A true CN114246925A (en) | 2022-03-29 |
Family
ID=80789578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011002501.5A Pending CN114246925A (en) | 2020-09-22 | 2020-09-22 | Traditional Chinese medicine essential oil and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114246925A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115449422A (en) * | 2022-09-14 | 2022-12-09 | 杭州香芝生物科技有限公司 | Method for extracting magnolia flower oil |
CN115708794A (en) * | 2023-01-09 | 2023-02-24 | 同芙集团(中国)股份有限公司 | Antibacterial essential oil |
CN116058388A (en) * | 2023-02-01 | 2023-05-05 | 徐宝华 | Composition capable of sterilizing and inhibiting viruses and application thereof |
CN116211962A (en) * | 2023-02-07 | 2023-06-06 | 广州美思生物技术有限公司 | Natural plant skin antibacterial liquid for removing mites, inhibiting bacteria, eliminating acnes and improving seborrheic dermatitis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853277A (en) * | 2017-05-12 | 2018-11-23 | 王月梅 | A kind of Traditional Chinese medicine disinfectant for acupuncture |
CN111280526A (en) * | 2020-03-26 | 2020-06-16 | 贾斌 | Mask for preventing pneumonia caused by influenza virus and/or novel coronavirus and preparation method thereof |
CN111297949A (en) * | 2020-03-19 | 2020-06-19 | 王鹏 | Essential oil mask and preparation method thereof |
-
2020
- 2020-09-22 CN CN202011002501.5A patent/CN114246925A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853277A (en) * | 2017-05-12 | 2018-11-23 | 王月梅 | A kind of Traditional Chinese medicine disinfectant for acupuncture |
CN111297949A (en) * | 2020-03-19 | 2020-06-19 | 王鹏 | Essential oil mask and preparation method thereof |
CN111280526A (en) * | 2020-03-26 | 2020-06-16 | 贾斌 | Mask for preventing pneumonia caused by influenza virus and/or novel coronavirus and preparation method thereof |
Non-Patent Citations (10)
Title |
---|
MUHAMMAD ASIF等: "COVID‑19 and therapy with essential oils having antiviral,anti‑inflammatory, and immunomodulatory properties", 《INFLAMMOPHARMACOLOGY》 * |
周峰等: "十二种中药挥发油及其滤液体外抗菌活性研究", 《食品科学》 * |
姜程曦等: "莪术油注射液协同治疗新型冠状病毒肺炎(COVID-19)可行性浅析", 《中草药》 * |
张婷婷等: "辛夷挥发油GC-MS分析及其抗氧化、抗菌活性", 《食品科学》 * |
张金宝等: "蛇床子挥发油的提取方法及其化学成分的气相色谱分析", 《理化检验-化学分册》 * |
徐小娜等: "基于 GC-MS 结合 HELP 法的药对金银花—连翘及其单味药挥发性化学成分分析", 《南昌工程学院学报》 * |
杨超等: "蒲公英挥发油成分分析及其抗炎抗肿瘤活性研究", 《中华中医药杂志》 * |
詹益兴等: "《绿色精细化工——天然产品制造法(第2集)》", 31 July 2006, 科学技术文献出版社 * |
豆康宁等: "响应面优化超声波辅助提取甘草精油工艺研究", 《中国调味品》 * |
银艳桃等: "中药挥发油预防新型冠状病毒肺炎刍议", 《医学争鸣》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115449422A (en) * | 2022-09-14 | 2022-12-09 | 杭州香芝生物科技有限公司 | Method for extracting magnolia flower oil |
CN115708794A (en) * | 2023-01-09 | 2023-02-24 | 同芙集团(中国)股份有限公司 | Antibacterial essential oil |
CN116058388A (en) * | 2023-02-01 | 2023-05-05 | 徐宝华 | Composition capable of sterilizing and inhibiting viruses and application thereof |
CN116211962A (en) * | 2023-02-07 | 2023-06-06 | 广州美思生物技术有限公司 | Natural plant skin antibacterial liquid for removing mites, inhibiting bacteria, eliminating acnes and improving seborrheic dermatitis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Wyk et al. | Medicinal plants of the world | |
CN106538638B (en) | A kind of Chinese medicine antiseptic and preparation method thereof | |
Jaiarj et al. | Anticough and antimicrobial activities of Psidium guajava Linn. leaf extract | |
Batiha et al. | A review of the bioactive components and pharmacological properties of Lavandula species | |
Sultana et al. | Cough suppressant herbal drugs: A review | |
CN114246925A (en) | Traditional Chinese medicine essential oil and application thereof | |
Manganelli et al. | Ethnopharmacobotanical studies of the Tuscan Archipelago | |
US8496978B2 (en) | Anti-fever botanical composition and uses thereof | |
WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
CN102940719A (en) | Chinese herbal medicine feed additive for treating dairy cow mastitis | |
Natarajan et al. | An ethnopharmacological study from Thane district, Maharashtra, India: Traditional knowledge compared with modern biological science | |
CN112841233A (en) | Traditional Chinese medicine pesticide | |
Kaushik et al. | Chemical constituents, pharmacological activities, and uses of common ayurvedic medicinal plants: a future source of new drugs | |
Bary et al. | Moroccan traditional medicine for the prevention and relief of corona virus COVID-19 symtomes | |
Hurinanthan | Anti-HIV activity of selected South African medicinal plants | |
CN104491121A (en) | Anti-bacterial essence solution for treating respiratory diseases and preparation method of anti-bacterial essence solution | |
Raghunathan | An ethnomedicinal survey of medicinal plants utilized by folk people of the Thrissur forest circle, Kerala | |
Usman | Poisonous Herbal Plants: NA | |
Mounika et al. | Invitro evaluation of antimicrobial activity of Clove buds (Euginea aromatica) | |
ERUÇAR et al. | Ethnobotanical records of medicinal plants of Turkey effective on stress management Complied with the literature survey in their chemical content and activities | |
Otimanam et al. | Cutaneous wound healing activity of herbal ointment containing Tetrapleura tetraptera fruit extract | |
CN104814047A (en) | Traditional Chinese medicine composition disinfectant for disinfecting B ultrasonic rooms | |
Singh et al. | Antiviral effects of medicinal plants and their active phytochemical constituents against respiratory diseases and associated biological functions | |
Lawal et al. | A Study of the Phytochemical Properties and Synergistic Antibacterial Activity of Annona comosus (LINN) Merr. Peel and Citrus senensis Peel Extracts on Aeromonas hydrophila and Salmonella species. | |
Dhar et al. | Medicinal Plants of India |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220329 |